

Supporting information

TfOH-mediated [2+2+2] Cycloadditions of Ynamides with Two Discrete Nitriles: Access to 4-Aminopyrimidine Derivatives

Ping Chen,^a Cai-xia Song,^a Wan-shu Wang,^a Xue-liang Yu^a and Yu Tang^{a,b*}

^a School of Pharmaceutical Science and Technology, Key Laboratory for Modern Drug Delivery & High-Efficiency, Tianjin University, Tianjin, 300072 P. R. China

^b School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao, China.
e-mail: tangyu@ouc.edu.cn

Table of Contents


1 General information	S1
2 General procedure and experimental characterization data	S1
3 Spectra data	S14

1 General Information

Unless otherwise mentioned, all reactions were performed in flame-dried glassware under air. Solvents were distilled prior to use. Reagents were used as purchased from commercial available unless otherwise noted. Chromatographic separations were performed using Kangbino 48-75 Å SiO₂. ¹H and ¹³C NMR spectra were obtained on 500 MHz or 600 MHz spectrometers using CDCl₃ with TMS or residual solvent as standard unless otherwise noted. Melting points were determined using a melting point apparatus and were uncorrected/calibrated. TLC analysis was performed using Kangbino glass-backed plates (60 Å, 250 µm) and visualized using UV and Iodine stains. Low-resolution mass spectra were obtained using an Agilent 1100 series LS/MSD. All spectral data obtained for new compounds are reported here.

Experimental Section


General Procedure 1 for the Synthesis of ynamides (**1a, b, d –1n**)



To a solution of phenylacetylene (1.00 g, 9.80 mmol) in acetone (100 mL) was added NBS (1.92 g, 10.78 mmol) and AgNO₃ (0.17 g, 0.98 mmol). The resulting solution was stirred under nitrogen at room temperature for 4 hours. After removing excess acetone the reaction was quenched with water, and the organic layer was extracted with EtOAc three times, dried over MgSO₄, and concentrated under reduced pressure. The residue was eluted through a short silica column (petroleum ether) to obtain the bromoalkyne (1.50 g, 85%).

To a dried flask was added 4-methyl-N-phenylbenzenesulfonamide (1.20 g, 4.85 mmol), CuSO₄·5H₂O (100 mg, 0.40 mmol), 1,10-phenanthroline (145 mg, 0.81 mmol) and K₂CO₃ (1.40 mg, 10.01 mmol), bromoalkyne (730 mg, 4.04 mmol) and this mixture was subsequently treated with anhydrous toluene (100 mL) and the bromoalkyne. The flask was charged with nitrogen, and the solution was heated at 80°C overnight. After completion, the crude reaction mixture was cooled to room temperature, filtered through CeliteTM, and concentrated in vacuo. Purification of the crude residue using silica gel flash column chromatography yielded the pure ynamide **1a** as white solid (980 mg, 57%).

General Procedure 1' for the Synthesis of ynamides (**1c**)



CuCl_2 (0.35g, 2.05 mmol), 4-methyl-N-phenylbenzenesulfonamide (12.60 g, 51.33 mmol), Na_2CO_3 (2.15 g, 20.30 mmol) were added to a flame-dried flask. The flask was purged with oxygen for 15 min and a solution of pyridine (1.61 ml, 20.30 mmol) in dry toluene (0.2 M) was heated at 70 °C. After 15 min, a solution of trimethylsilylacetylene in dry toluene (0.2 M) was added over 4 h. The mixture was allowed to stir at 70 °C for another 4 h and was then cooled to rt. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography to obtain the corresponding product (1.89 g, 54%).

To a solution of the corresponding ynamide (1.89 g, 5.51 mmol) in THF (50 mL) was added the solution of TBAF (2.88 g, 11.02 mmol) in THF (30 mL) slowly at rt. Then the resulting solution was stirred at room temperature for 30 min. The reaction mixture was concentrated and the residue was purified by flash chromatography to obtain the ynamide **1c** (1.20 g, 45% over two steps).

4-methyl-N-phenyl-N-(phenylethynyl)benzenesulfonamide (1a)

Following the general procedure 1: white solid, mp: 103-105 °C, 70%; $R_f = 0.4$ (5% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.62 (d, $J = 7.8$ Hz, 2H), 7.41 - 7.28 (m, 12H), 2.44 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 145.03, 138.94, 132.88, 131.47, 129.54, 129.13, 128.32, 128.29, 128.00, 126.32, 122.62, 82.98, 70.48, 21.76; mass spectrum (ESI): m/e (% relative intensity) 370.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{21}\text{H}_{17}\text{NO}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 370.0878, found 370.0878.

N-(cyclopropylethynyl)-N,4-dimethylbenzenesulfonamide (1b)

Following the general procedure 1: white solid, mp: 48-50 °C, 47%; $R_f = 0.45$ (30% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.77 (d, $J = 8.4$ Hz, 2H), 7.36 (d, $J = 7.8$ Hz, 2H), 2.99 (s, 3H), 2.46 (s, 3H), 1.31 - 1.24 (m, 1H), 0.82 - 0.73 (m, 2H), 0.66 - 0.58 (m, 2H); ^{13}C NMR (150 MHz, CDCl_3) δ 145.33, 134.08, 130.47, 128.66, 73.79, 71.28, 40.22, 22.50, 9.55, 0.00; mass spectrum (ESI): m/e (% relative intensity) 272.1 (100) ($\text{M}+\text{Na}$) $^+$.

N-ethynyl-4-methyl-N-phenylbenzenesulfonamide (1c)

Following the general procedure 1: pale yellow solid, mp: 69-70 °C, 45%; $R_f = 0.45$ (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.58 (d, $J = 8.4$ Hz, 2H), 7.35 - 7.23 (m, 7H), 2.84 (s, 1H), 2.45 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 145.12, 138.23, 132.84, 129.57, 129.16, 128.46, 128.27, 126.32, 76.53, 58.91, 21.76; mass spectrum (ESI): m/e (% relative intensity) 294.1 (100) ($\text{M}+\text{Na}$) $^+$.

(R)-4-phenyl-3-((triisopropylsilyl)ethynyl)oxazolidin-2-one (1d)

Following the general procedure 1: colorless oil, 46%; $R_f = 0.45$ (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.45 - 7.38 (m, 3H), 7.37 - 7.33 (m, 2H), 5.06 (dd, $J = 7.8, 8.4$ Hz, 1H), 4.73 (dd, $J = 8.4, 9.0$ Hz, 1H), 4.28 (dd, $J = 7.8, 9.0$ Hz, 1H), 0.90 (s, 21H); ^{13}C NMR (150 MHz, CDCl_3) δ 155.32, 135.79, 129.47, 129.18, 127.17, 91.87, 71.98, 70.56, 62.32, 18.39, 11.05; mass spectrum (ESI): m/e (% relative intensity) 366.2 (100) ($\text{M}+\text{Na}$) $^+$.

(S)-4-benzyl-3-(phenylethynyl)oxazolidin-2-one (1e)

Following the general procedure 1: white solid, mp: 96-98 °C, 63%; $R_f = 0.35$ (30% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.51 - 7.43 (m, 2H), 7.40 - 7.27 (m, 6H), 7.27 - 7.23 (m, 2H), 4.42 - 4.33 (m, 2H), 4.21 - 4.14 (m, 1H), 3.33 - 3.26 (m, 1H), 3.06 - 2.98 (m, 1H); ^{13}C NMR (150 MHz,

CDCl_3) δ 155.50, 134.20, 131.68, 129.43, 129.10, 128.34, 128.30, 127.59, 122.18, 77.90, 73.33, 67.48, 58.53, 38.04; mass spectrum (ESI): m/e (% relative intensity) 300.1 (100) ($\text{M}+\text{Na}$)⁺.

N-(hex-1-yn-1-yl)-N,4-dimethylbenzenesulfonamide (1f)

Following the general procedure 1: colorless oil, 35%; $R_f = 0.4$ (20% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl_3) δ 7.78 (d, $J = 7.2$ Hz, 2H), 7.35 (d, $J = 7.8$ Hz, 2H), 3.01 (s, 3H), 2.46 (s, 3H), 2.24 (t, $J = 7.2$ Hz, 2H), 1.49 - 1.42 (m, 2H), 1.41 - 1.32 (m, 2H), 0.90 (t, $J = 7.2$ Hz, 3H); ¹³C NMR (150 MHz, CDCl_3) δ 144.44, 133.21, 129.61, 127.84, 74.84, 68.61, 39.39, 30.96, 21.83, 21.64, 18.03, 13.58; mass spectrum (ESI): m/e (% relative intensity) 288.1 (100) ($\text{M}+\text{Na}$)⁺.

(S)-4-phenyl-3-(phenylethynyl)oxazolidin-2-one (1g)

Following the general procedure 1: white solid, mp: 144-146 °C, 50%; $R_f = 0.4$ (30% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl_3) δ 7.52 - 7.37 (m, 5H), 7.30 - 7.18 (m, 5H), 5.14 (dd, $J = 7.8, 7.8$ Hz, 1H), 4.78 (dd, $J = 7.8, 7.8$ Hz, 1H), 4.31 (dd, $J = 7.8, 7.8$ Hz, 1H); ¹³C NMR (150 MHz, CDCl_3) δ 155.62, 136.03, 131.49, 129.57, 129.36, 128.18, 128.10, 126.94, 122.11, 78.02, 72.84, 70.81, 62.23; mass spectrum (ESI): m/e (% relative intensity) 286.1 (100) ($\text{M}+\text{Na}$)⁺.

N,4-dimethyl-N-(phenylethynyl)benzenesulfonamide (1h)

Following the general procedure 1: white solid, mp: 79-81 °C, 49%; $R_f = 0.3$ (20% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl_3) δ 7.84 (d, $J = 7.8$ Hz, 2H), 7.40 - 7.33 (m, 4H), 7.32 - 7.26 (m, 3H), 3.15 (s, 3H), 2.46 (s, 3H); ¹³C NMR (150 MHz, CDCl_3) δ 144.87, 133.16, 131.43, 129.85, 128.30, 127.88, 122.68, 83.93, 69.02, 39.35, 21.71; mass spectrum (ESI): m/e (% relative intensity) 308.1 (100) ($\text{M}+\text{Na}$)⁺.

3-(phenylethynyl)oxazolidin-2-one (1i)

Following the general procedure 1: white solid, mp: 84-85 °C, 62%; $R_f = 0.25$ (20% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl_3) δ 7.47 - 7.41 (m, 2H), 7.33 - 7.28 (m, 3H), 4.48 (t, $J = 7.8$ Hz, 2H), 4.01 (t, $J = 7.8$ Hz, 2H); ¹³C NMR (150 MHz, CDCl_3) δ 155.91, 131.59, 128.32, 128.22, 122.17, 78.96, 71.21, 63.05, 47.06; mass spectrum (ESI): m/e (% relative intensity) 210.1 (100) ($\text{M}+\text{Na}$)⁺.

N-methyl-N-(phenylethynyl)methanesulfonamide (1j)

Following the general procedure 1: white solid, mp: 58-60 °C, 61%; $R_f = 0.45$ (30% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl_3) δ 7.45 - 7.38 (m, 2H), 7.33 - 7.28 (m, 3H), 3.30 (s, 3H), 3.13 (m, 3H); ¹³C NMR (150 MHz, CDCl_3) δ 131.55, 128.35, 128.13, 122.34, 82.99, 69.47, 39.26, 36.78; mass spectrum (ESI): m/e (% relative intensity) 232.0 (100) ($\text{M}+\text{Na}$)⁺.

3-(*p*-tolylethynyl)oxazolidin-2-one (1k)

Following the general procedure 1: white solid, mp: 124-126 °C, 52%; $R_f = 0.3$ (20% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl_3) δ 7.33 (d, $J = 7.8$ Hz, 2H), 7.11 (d, $J = 7.8$ Hz, 2H), 4.48 (t, $J = 8.4$ Hz, 2H), 4.00 (t, $J = 8.4$ Hz, 2H), 2.34 (s, 3H); ¹³C NMR (150 MHz, CDCl_3) δ 155.98, 138.43, 131.64, 129.08, 119.00, 78.25, 71.23, 63.01, 47.10, 21.48; mass spectrum (ESI): m/e (% relative intensity) 224.1 (100) ($\text{M}+\text{Na}$)⁺.

N-benzyl-N-((4-methoxyphenyl)ethynyl)-4-methylbenzenesulfonamide (1l)

Following the general procedure 1: white solid, mp: 88-90 °C, 15%; R_f = 0.6 (30% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.78 (d, J = 7.8 Hz, 2H), 7.36 - 7.27 (m, 7H), 7.19 (d, J = 7.8 Hz, 2H), 6.77 (d, J = 7.8 Hz, 2H), 4.56 (s, 2H), 3.77 (s, 3H), 2.44 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 159.42, 144.54, 134.74, 134.62, 133.19, 129.68, 128.86, 128.49, 128.26, 127.77, 114.73, 113.86, 81.21, 70.95, 55.79, 55.30, 21.67; mass spectrum (ESI): m/e (% relative intensity) 414.1 (100) ($\text{M}+\text{Na}$) $^+$.


3-((4-fluorophenyl)ethynyl)oxazolidin-2-one (1m)

Following the general procedure 1: white solid, mp: 114-116 °C, 56%; R_f = 0.3 (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.45 - 7.40 (m, 2H), 7.03 - 6.98 (m, 2H), 4.49 (t, J = 7.8 Hz, 2H), 4.00 (t, J = 7.8 Hz, 2H); ^{13}C NMR (150 MHz, CDCl_3) δ 163.35 - 161.70 (d, J = 247.5 Hz), 155.92, 133.72 - 133.66 (d, J = 9.0 Hz), 118.20 - 118.18 (d, J = 3.0 Hz), 115.69 - 115.54 (d, J = 22.5 Hz), 78.58, 70.16, 63.08, 63.06, 47.00; mass spectrum (ESI): m/e (% relative intensity) 228.0 (100) ($\text{M}+\text{Na}$) $^+$.

Ethyl 3-(N,4-dimethylphenylsulfonamido)propiolate (1n)

Following the general procedure 1: white solid, mp: 79-80 °C, 43%; R_f = 0.3 (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.82 (d, J = 7.8 Hz, 2H), 7.39 (d, J = 7.8 Hz, 2H), 4.23 (q, J = 7.2 Hz, 2H), 3.17 (s, 3H), 2.47 (s, 3H), 1.31 (t, J = 7.2 Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 154.14, 145.70, 133.10, 130.15, 127.87, 83.54, 0.65.95, 61.64, 38.62, 21.73, 14.17; mass spectrum (ESI): m/e (% relative intensity) 304.1 (100) ($\text{M}+\text{Na}$) $^+$; m/e calcd for $\text{C}_{13}\text{H}_{15}\text{NO}_4\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 304.0619, found 304.0632.

General Procedure A for TfOH-Mediated [2+2+2] Cycloadditions of Ynamides with Acetonitrile (3a–3n).



To a suspension of ynamide (0.15 mmol) and 4 Å MS (20.0 mg) in dry acetonitrile (2.00 mL) was added TfOH dropwise (21.0 μl , 0.24 mmol) via a syringe pump at -40 °C under nitrogen atmosphere. The reaction was monitored by TLC. When progress appeared to be completed after about 1.5 h at the same temperature, the saturated sodium bicarbonate solution was added to the mixture and the resulting mixture was extracted with EtOAc. The organic layers were washed with sat aq NaCl and dried over MgSO_4 . Filtration and concentration of the mixture in vacuo afforded the crude product that was purified by flash silica gel column chromatography [gradient eluent: EtOAc in petroleum ether] to obtain the corresponding products.

N-(2,6-dimethyl-5-phenylpyrimidin-4-yl)-4-methyl-N-phenylbenzenesulfonamide (3a)

Following the general procedure A: white solid, mp: 163-165 °C, 97%; R_f = 0.5 (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.66 (d, J = 7.8 Hz, 2H), 7.32 - 7.18 (m, 5H), 7.11 - 7.06 (m, 1H), 7.01 - 6.94 (m, 2H), 6.89 (d, J = 7.2 Hz, 2H), 6.58 (d, J = 7.8 Hz, 2H), 2.70 (s, 3H), 2.42 (s, 3H), 2.22 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 167.89, 165.69, 160.12, 143.54, 138.91, 136.57, 133.82, 129.51, 129.42, 129.05, 128.59, 128.42, 128.29, 127.64, 127.50, 127.46, 25.38, 22.96, 21.66; mass spectrum (ESI): m/e (% relative intensity) 452.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{25}\text{H}_{23}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 452.1409, found 452.1429.

N-(5-cyclopropyl-2,6-dimethylpyrimidin-4-yl)-N,4-dimethylbenzenesulfonamide (3b)

Following the general procedure A: white solid, mp: 140-141 °C, 93%; R_f = 0.25 (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.67 (d, J = 7.8 Hz, 2H), 7.30 (d, J = 7.8 Hz, 2H), 3.09 (s, 3H), 2.65 (s, 3H), 2.51 (s, 3H), 2.44 (s, 3H), 1.96 - 1.86 (m, 1H), 1.22 - 1.12 (m, 2H), 0.66 - 0.53 (m, 2H); ^{13}C NMR (150 MHz, CDCl_3) δ 171.04, 164.48, 160.86, 143.71, 135.08, 129.25, 128.51, 127.83, 36.39, 25.15, 22.79, 21.58, 10.08, 8.52; mass spectrum (ESI): m/e (% relative intensity) 354.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 354.1252, found 354.1266.

N-(2,6-dimethylpyrimidin-4-yl)-4-methyl-N-phenylbenzenesulfonamide (3c)

Following the general procedure A: white solid, mp: 138-141 °C, 91%; R_f = 0.8 (50% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 8.00 (d, J = 7.5 Hz, 2H), 7.55 - 7.45 (m, 3H), 7.36 - 7.26 (m, 4H), 5.94 (s, 1H), 2.57 (s, 3H), 2.43 (s, 3H), 2.24 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 167.07, 166.42, 160.83, 144.28, 137.41, 137.31, 130.48, 130.01, 129.62, 128.94, 105.53, 25.42, 24.15, 21.65; mass spectrum (ESI): m/e (% relative intensity) 376.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 376.1096, found 376.1112.

(R)-3-(2,6-dimethylpyrimidin-4-yl)-4-phenyloxazolidin-2-one (3d)

Following the general procedure A: colorless oil, 87%; R_f = 0.7 (50% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.87 (s, 1H), 7.44 - 7.25 (m, 5H), 5.88 - 5.78 (m, 1H), 4.79 (t, J = 8.7 Hz, 1H), 4.43 - 4.33 (m, 1H), 2.45 (s, 3H), 2.44 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 167.81, 166.78, 156.27, 154.72, 139.63, 128.91, 128.42, 126.45, 105.72, 70.34, 57.99, 25.58, 24.34; mass spectrum (ESI): m/e (% relative intensity) 292.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{15}\text{H}_{15}\text{N}_3\text{O}_2\text{Na}$ ($\text{M}+\text{Na}$) $^+$ 292.1062, found 292.1064.

3-(5-(4-fluorophenyl)-2,6-dimethylpyrimidin-4-yl)oxazolidin-2-one (3e)

Following the general procedure A: white solid, mp: 153-155 °C, 82%; R_f = 0.6 (60% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.28 - 7.19 (m, 2H), 7.17 - 7.07 (m, 2H), 4.33 (t, J = 7.8 Hz, 2H), 4.03 (t, J = 7.8 Hz, 2H), 2.70 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 167.96, 166.39, 163.12 - 161.48 (d, J = 246.1 Hz), 155.91, 154.44, 131.20 - 131.14 (d, J = 9.0 Hz), 130.50 - 130.48 (d, J = 3.0 Hz), 125.49, 115.63 - 115.48 (d, J = 22.5 Hz), 62.66, 45.53, 25.60, 23.13; ^{19}F NMR (564 MHz, CDCl_3): δ -113.65; mass spectrum (ESI): m/e (% relative intensity) 310.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{15}\text{H}_{14}\text{FN}_3\text{O}_2\text{Na}$ ($\text{M}+\text{Na}$) $^+$ 310.0968, found 310.0981.

3-(2,6-dimethyl-5-(*p*-tolyl)pyrimidin-4-yl)oxazolidin-2-one (3f)

Following the general procedure A: white solid, mp: 103-104 °C, 93%; R_f = 0.4 (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.23 (d, J = 7.8 Hz, 2H), 7.14 (d, J = 7.8 Hz, 2H), 4.29 (t, J = 7.8 Hz, 2H), 3.91 (t, J = 7.8 Hz, 2H), 2.70 (s, 3H), 2.39 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.04, 166.08, 155.88, 154.66, 137.76, 131.33, 129.25, 129.10, 126.57, 62.62, 45.63, 25.58, 23.09, 21.30; mass spectrum (ESI): m/e (% relative intensity) 306.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{16}\text{H}_{17}\text{N}_3\text{O}_2\text{Na}$ ($\text{M}+\text{Na}$) $^+$ 306.1218, found 306.1231.

(R)-3-(2,6-dimethyl-5-phenylpyrimidin-4-yl)-4-phenyloxazolidin-2-one (3g)

Following the general procedure A: white solid, mp: 58-60 °C, 86%; R_f = 0.3 (20% EtOAc/Petroleum

Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.63 - 7.37 (m, 4H), 7.36 - 7.30 (m, 3H), 7.28 - 7.23 (m, 2H), 6.90 - 6.57 (m, 1H), 5.56 (dd, $J = 9.0, 9.6$ Hz, 1H), 4.60 (dd, $J = 9.0, 9.0$ Hz, 1H), 4.15 (dd, $J = 9.0, 9.6$ Hz, 1H), 2.66 (s, 3H), 2.23 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.26, 166.16, 155.36, 155.06, 136.34, 134.17, 129.11, 128.82, 128.13, 128.10, 128.06, 70.06, 60.64, 25.56, 23.12; mass spectrum (ESI): m/e (% relative intensity) 368.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{21}\text{H}_{19}\text{N}_3\text{O}_2\text{Na}$ ($\text{M}+\text{Na}$) $^+$ 368.1375, found 368.1390.

(S)-4-benzyl-3-(2,6-dimethyl-5-phenylpyrimidin-4-yl)oxazolidin-2-one (3h)

Following the general procedure A: white solid, mp: 43-45 °C, 78%; $R_f = 0.45$ (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.53 - 7.31 (m, 4H), 7.30 - 7.18 (m, 4H), 7.09 (d, $J = 7.2$ Hz, 2H), 4.66 - 4.56 (m, 1H), 4.13 (t, $J = 8.5$ Hz, 1H), 3.96 (t, $J = 8.5$ Hz, 1H), 3.20 - 3.15 (m, 1H), 2.74 (s, 3H), 2.67 - 2.56 (m, 1H), 2.36 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.22, 166.52, 155.16, 154.92, 135.33, 134.32, 128.86, 128.84, 128.51, 128.15, 127.87, 127.25, 67.99, 57.35, 38.97, 25.74, 23.19; mass spectrum (ESI): m/e (% relative intensity) 382.2 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{22}\text{H}_{21}\text{N}_3\text{O}_2\text{Na}$ ($\text{M}+\text{Na}$) $^+$ 382.1531, found 382.1538.

3-(2,6-dimethyl-5-phenylpyrimidin-4-yl)oxazolidin-2-one (3i)

Following the general procedure A: white solid, mp: 125-127 °C, 89%; $R_f = 0.45$ (50% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.45 - 7.40 (m, 2H), 7.39 - 7.35 (m, 1H), 7.26 (d, $J = 7.2$ Hz, 2H), 4.29 (t, $J = 7.7$ Hz, 2H), 3.93 (t, $J = 7.7$ Hz, 2H), 2.71 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 167.91, 166.29, 155.83, 154.62, 134.45, 129.30, 128.50, 128.03, 126.54, 62.63, 45.63, 25.60, 23.09; mass spectrum (ESI): m/e (% relative intensity) 292.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{15}\text{H}_{15}\text{N}_3\text{O}_2\text{Na}$ ($\text{M}+\text{Na}$) $^+$ 292.1062, found 292.1065.

N-(2,6-dimethyl-5-phenylpyrimidin-4-yl)-N-methylmethanesulfonamide (3j)

Following the general procedure A: white solid, mp: 117-118 °C, 95%; $R_f = 0.4$ (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.49 - 7.45 (m, 2H), 7.43 - 7.38 (m, 1H), 7.32 (d, $J = 7.2$ Hz, 2H), 3.19 (s, 3H), 2.80 (s, 3H), 2.71 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.28, 166.23, 159.98, 133.90, 129.60, 128.83, 128.26, 127.51, 39.85, 36.88, 25.65, 23.22; mass spectrum (ESI): m/e (% relative intensity) 314.1 (100) ($\text{M}+\text{H}$) $^+$; HRMS calcd for $\text{C}_{14}\text{H}_{17}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 314.0939 found 314.0952.

N-(5-butyl-2,6-dimethylpyrimidin-4-yl)-N,4-dimethylbenzenesulfonamide (3k)

Following the general procedure A: white solid, mp: 91-93 °C, 84%; $R_f = 0.45$ (30% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.62 (d, $J = 7.8$ Hz, 2H), 7.31 (d, $J = 7.8$ Hz, 2H), 3.02 (s, 3H), 2.91 (t, $J = 7.7$ Hz, 2H), 2.56 (s, 3H), 2.46 (s, 3H), 2.45 (s, 3H), 1.57 - 1.48 (m, 2H), 1.47 - 1.39 (m, 2H), 0.98 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.67, 164.59, 160.27, 143.85, 133.92, 129.80, 129.12, 129.00, 37.34, 31.32, 26.96, 25.00, 22.89, 22.30, 21.60, 13.86; mass spectrum (ESI): m/e (% relative intensity) 370.2 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{18}\text{H}_{25}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 370.1565, found 370.1578.

N-benzyl-N-(5-(4-methoxyphenyl)-2,6-dimethylpyrimidin-4-yl)-4-methylbenzenesulfonamide (3l)

Following the general procedure A: pale yellow solid, mp: 146-148 °C, 91%; $R_f = 0.4$ (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.58 (d, $J = 7.8$ Hz, 2H), 7.25 (d, $J = 8.0$ Hz,

2H), 7.20 - 7.15 (m, 1H), 7.13 - 7.07 (m, 2H), 6.85 (d, J = 8.0 Hz, 2H), 6.78 (d, J = 7.4 Hz, 2H), 6.73 (d, J = 8.0 Hz, 2H), 4.41 (s, 2H), 3.87 (s, 3H), 2.67 (s, 3H), 2.44 (s, 3H), 2.23 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.76, 165.87, 159.18, 157.98, 143.78, 136.07, 134.70, 131.18, 130.93, 129.44, 129.13, 128.93, 128.19, 127.77, 126.05, 113.52, 55.27, 53.17, 25.38, 23.37, 21.62; mass spectrum (ESI): m/e (% relative intensity) 496.2 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{27}\text{H}_{27}\text{N}_3\text{O}_4\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 496.1671, found 496.1687.


***N*-(2,6-dimethyl-5-phenylpyrimidin-4-yl)-*N*,4-dimethylbenzenesulfonamide (3m)**

Following the general procedure A: white solid, mp: 135-137 °C, 94%; R_f = 0.2 (50% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.74 (d, J = 7.8 Hz, 2H), 7.51 - 7.46 (m, 2H), 7.45 - 7.40 (m, 1H), 7.35 (d, J = 7.2 Hz, 2H), 7.28 (d, J = 7.8 Hz, 2H), 2.74 (s, 3H), 2.65 (s, 3H), 2.43 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.14, 166.22, 159.71, 143.66, 135.87, 134.27, 129.70, 129.10, 128.91, 128.71, 128.53, 128.10, 36.72, 25.37, 23.29, 21.59; mass spectrum (ESI): m/e (% relative intensity) 390.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{20}\text{H}_{21}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 390.1252, found 390.1258.

Ethyl 4-(*N*,4-dimethylphenylsulfonamido)-2,6-dimethylpyrimidine-5-carboxylate (3n)

Following the general procedure A: white solid, mp: 80-82 °C, 86%; R_f = 0.35 (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.57 (d, J = 7.9 Hz, 2H), 7.28 (d, J = 7.9 Hz, 2H), 4.46 (q, J = 7.1 Hz, 2H), 3.13 (s, 3H), 2.66 (s, 3H), 2.56 (s, 3H), 2.43 (s, 3H), 1.44 (t, J = 7.1 Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 167.93, 167.75, 165.85, 159.07, 144.14, 134.21, 129.47, 128.26, 121.13, 61.99, 36.36, 25.68, 23.47, 21.60, 14.02; mass spectrum (ESI): m/e (% relative intensity) 386.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 386.1150, found 386.1147.

General Procedure B for TfOH-Mediated [2+2+2] Cycloadditions of Ynamides with Various Nitrile (4a–4s).



To a stirring suspension of ynamide (0.13 mmol), nitriles (1.20 mmol) and 4 Å MS (20.0 mg) in dry dichloromethane (2.00 mL) was added TfOH dropwise (21.0 μl , 0.24 mmol) via a syringe pump at -40 °C under nitrogen atmosphere. The reaction was monitored by TLC. When progress appeared to be completed after about 1.5 h at the same temperature, the saturated sodium bicarbonate solution was added to the mixture and the resulting mixture was extracted with EtOAc. The organic layers were washed with sat aq NaCl and dried over MgSO_4 . Filtration and concentration of the mixture in vacuo afforded the crude product that was purified by flash silica gel column chromatography [gradient eluent: EtOAc in petroleum ether] to obtain corresponding product s.

4-methyl-*N*-phenyl-*N*-(2,5,6-triphenylpyrimidin-4-yl)benzenesulfonamide (4a)

Following the general procedure B: white solid, mp: 218-220 °C, 91%; R_f = 0.7 (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 8.34 (d, J = 6.6 Hz, 2H), 7.67 (d, J = 7.2 Hz, 2H), 7.57 - 7.45 (m, 3H), 7.41 (d, J = 7.2 Hz, 2H), 7.32 - 7.16 (m, 8H), 7.13 - 6.95 (m, 5H), 6.75 (d, J = 7.2 Hz, 2H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 167.33, 162.99, 161.49, 143.53, 138.64,

137.76, 137.27, 137.11, 133.93, 131.01, 130.47, 129.98, 129.17, 129.12, 129.00, 128.91, 128.84, 128.66, 128.44, 128.40, 128.33, 127.79, 127.71, 127.67, 21.76; mass spectrum (ESI): m/e (% relative intensity) 576.2 (100) ($M+Na$)⁺; HRMS calcd for $C_{35}H_{27}N_3O_2SNa$ ($M+Na$)⁺ 576.1722, found 576.1720.

Ethyl 4-(N,4-dimethylphenylsulfonamido)-2,6-diphenylpyrimidine-5-carboxylate (4b)

Following the general procedure B: white solid, mp: 172-174 °C, 83%; R_f = 0.5 (20% EtOAc/Petroleum Ether); ¹H NMR (400 MHz, CDCl₃) δ 8.23 (d, J = 7.2 Hz, 2H), 7.85 - 7.76 (m, 2H), 7.72 (d, J = 8.2 Hz, 2H), 7.53 - 7.45 (m, 4H), 7.44 - 7.38 (m, 2H), 7.31 (d, J = 8.1 Hz, 2H), 4.30 (q, J = 7.2 Hz, 2H), 3.26 (s, 3H), 2.45 (s, 3H), 1.17 (t, J = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.72, 166.13, 164.09, 160.49, 144.09, 137.69, 136.18, 134.42, 131.63, 130.37, 129.51, 128.76, 128.71, 128.49, 122.84, 62.11, 37.49, 21.65, 13.73; mass spectrum (ESI): m/e (% relative intensity) 510.1 (100) ($M+Na$)⁺; HRMS calcd for $C_{27}H_{25}N_3O_4SNa$ ($M+Na$)⁺ 510.1463, found 510.1478.

N,4-dimethyl-N-(2,5,6-triphenylpyrimidin-4-yl)benzenesulfonamide (4c)

Following the general procedure B: white solid, mp: 207-210 °C, 87%; R_f = 0.5 (10% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl₃) δ 8.28 (d, J = 7.8 Hz, 2H), 7.81 (d, J = 7.8 Hz, 2H), 7.52 - 7.40 (m, 5H), 7.39 - 7.28 (m, 8H), 7.27 - 7.22 (m, 2H), 2.87 (s, 3H), 2.50 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 167.58, 163.07, 161.46, 143.59, 138.05, 136.84, 136.20, 134.21, 130.99, 130.56, 130.04, 129.34, 129.17, 128.92, 128.86, 128.50, 128.49, 128.37, 127.96, 127.86, 37.17, 21.67; mass spectrum (ESI): m/e (% relative intensity) 514.2 (100) ($M+Na$)⁺; HRMS calcd for $C_{30}H_{25}N_3O_2SNa$ ($M+Na$)⁺ 514.1565, found 514.1576.

N-(2,6-bis(2-chlorophenyl)-5-phenylpyrimidin-4-yl)-N-methylmethanesulfonamide (4d)

Following the general procedure B: white solid, mp: 89-91 °C, 60.6%; R_f = 0.7 (20% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl₃) δ 7.93 - 7.88 (m, 1H), 7.53 - 7.49 (m, 1H), 7.41 - 7.37 (m, 2H), 7.33 (d, J = 8.0 Hz, 1H), 7.31 - 7.23 (m, 5H), 7.22 - 7.05 (m, 4H), 3.36 (s, 3H), 2.85 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 167.13, 163.12, 161.14, 137.01, 136.64, 132.92, 132.68, 132.49, 132.46, 130.87, 130.79, 130.67, 129.97, 129.86, 129.66, 129.07, 128.48, 128.33, 128.26, 127.78, 126.99, 126.44, 125.33, 40.21, 37.00.; 506.0 (100) ($M+Na$)⁺; HRMS calcd for $C_{24}H_{19}Cl_2N_3O_2SNa$ ($M+Na$)⁺ 506.0473, found 506.0476.

N-benzyl-N-(2,6-bis(4-chlorophenyl)-5-(4-methoxyphenyl)pyrimidin-4-yl)-4-methylbenzenesulfonamide (4e)

Following the general procedure B: white solid, mp: 178-183 °C, 75%; R_f = 0.6 (20% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl₃) δ 8.23 (d, J = 8.1 Hz, 2H), 7.67 (d, J = 7.7 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.35 - 7.27 (m, 4H), 7.17 (d, J = 8.2 Hz, 2H), 7.14 - 7.10 (m, 1H), 7.07 - 7.02 (m, 2H), 6.80 (d, J = 7.4 Hz, 4H), 6.76 (d, J = 8.0 Hz, 2H), 4.49 (s, 2H), 3.84 (s, 3H), 2.50 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 166.62, 161.49, 160.18, 159.28, 143.91, 137.32, 136.53, 136.05, 135.39, 135.19, 134.26, 132.06, 131.42, 131.05, 129.63, 129.43, 129.32, 129.08, 128.73, 128.25, 128.18, 128.09, 127.85, 125.55, 113.65, 55.25, 54.24, 21.71; mass spectrum (ESI): m/e (% relative intensity) 688.1 (100) ($M+Na$)⁺; HRMS calcd for $C_{37}H_{29}Cl_2N_3O_3SNa$ ($M+Na$)⁺ 688.1204, found 688.1195.

N-benzyl-N-(2,6-bis(4-chlorophenyl)-5-phenylpyrimidin-4-yl)-4-methylbenzenesulfonamide (4f)

Following the general procedure B: white solid, mp: 276-279 °C (dec.), 90%; R_f = 0.4 (10% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl₃) δ 8.24 (d, J = 8.1 Hz, 2H), 7.62 (d, J = 7.8 Hz,

2H), 7.44 (d, J = 8.1 Hz, 2H), 7.37 - 7.23 (m, 8H), 7.17 (d, J = 8.1 Hz, 2H), 7.11 (d, J = 7.3 Hz, 1H), 7.07 - 6.97 (m, 4H), 6.73 (d, J = 7.7 Hz, 2H), 2.50 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 166.13, 162.10, 161.72, 143.67, 138.51, 137.34, 137.29, 135.99, 135.58, 135.46, 133.49, 131.28, 130.28, 129.92, 129.00, 128.89, 128.84, 128.67, 128.55, 128.48, 128.11, 127.99, 127.75, 21.74; mass spectrum (ESI): m/e (% relative intensity) 644.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{35}\text{H}_{25}\text{Cl}_2\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 644.0942, found 644.0955

Dimethyl-2,2'-(6-(*N*-methylmethysulfonamido)-5-phenylpyrimidine-2,4-diyl)diacetate (4g)

Following the general procedure B: pale yellow oil, 74%; R_f = 0.4 (50% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.50 - 7.45 (m, 2H), 7.44 - 7.41 (m, 1H), 7.34 (d, J = 7.3 Hz, 2H), 4.03 (s, 2H), 3.77 (s, 3H), 3.70 (s, 2H), 3.65 (s, 3H), 3.19 (s, 3H), 2.79 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.74, 169.72, 164.48, 162.62, 161.00, 132.76, 129.51, 129.05, 128.83, 128.69, 52.33, 52.29, 44.75, 41.58, 39.91, 37.00.; mass spectrum (ESI): m/e (% relative intensity) 430.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{18}\text{H}_{21}\text{N}_3\text{O}_6\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 430.1049, found 430.1062.

***N*-(2,6-dibutyl-5-phenylpyrimidin-4-yl)-4-methyl-*N*-phenylbenzenesulfonamide (4h)**

Following the general procedure B: white solid, mp: 57-59 °C, 78%; R_f = 0.8 (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.65 (d, J = 7.8 Hz, 2H), 7.32 - 7.23 (m, 3H), 7.19 (d, J = 7.8 Hz, 2H), 7.12 - 7.07 (m, 1H), 7.01 - 6.95 (m, 2H), 6.91 (d, J = 7.2 Hz, 2H), 6.59 (d, J = 7.8 Hz, 2H), 2.93 (t, J = 7.8 Hz, 2H), 2.46 (t, J = 7.8 Hz, 2H), 2.41 (s, 3H), 1.85 - 1.77 (m, 2H), 1.52 - 1.42 (m, 4H), 1.19 - 1.11 (m, 2H), 1.00 (t, J = 7.2 Hz, 3H), 0.72 (t, J = 7.2 Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 171.53, 169.45, 160.12, 143.33, 139.04, 136.85, 133.82, 129.71, 129.32, 129.00, 128.58, 128.28, 128.21, 127.73, 127.52, 127.43, 38.73, 35.04, 31.23, 30.67, 22.59, 22.51, 21.60, 14.04, 13.69; mass spectrum (ESI): m/e (% relative intensity) 536.2 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{31}\text{H}_{35}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 536.2348, found 536.2357.

***N*-(2,6-bis(2-methoxyethyl)-5-phenylpyrimidin-4-yl)-*N*-methylmethanesulfonamide (4i)**

Following the general procedure B: colorless oil, 76%; R_f = 0.45 (50% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.48 - 7.44 (m, 2H), 7.42 - 7.38 (m, 1H), 7.37 - 7.32 (m, 2H), 3.93 (t, J = 6.2 Hz, 2H), 3.71 (t, J = 6.2 Hz, 2H), 3.40 (s, 3H), 3.27 - 3.22 (m, 5H), 3.19 (s, 3H), 2.89 (t, J = 6.3 Hz, 2H), 2.79 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.62, 166.61, 160.24, 133.41, 129.93, 128.77, 128.30, 70.77, 70.54, 58.74, 58.66, 39.82, 38.94, 36.99, 35.18; mass spectrum (ESI): m/e (% relative intensity) 402.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{18}\text{H}_{25}\text{N}_3\text{O}_4\text{SNa}$ ($\text{M}+\text{Na}$) $^+$ 402.1463 found 402.1463.

4-methyl-*N*-phenyl-*N*-(5-phenyl-2,6-di(thiophen-2-yl)pyrimidin-4-yl)benzenesulfonamide (4j)

Following the general procedure B: white solid, mp: 68-71 °C, 93%; R_f = 0.6 (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 8.18 - 8.15 (m, 1H), 7.81 (d, J = 4.7 Hz, 1H), 7.64 (d, J = 7.7 Hz, 2H), 7.41 - 7.36 (m, 2H), 7.35 - 7.31 (m, 2H), 7.28 - 7.23 (m, 3H), 7.22 - 7.20 (m, 1H), 7.13 - 7.09 (m, 2H), 7.06 (d, J = 7.0 Hz, 2H), 7.04 - 7.00 (m, 2H), 6.75 (d, J = 7.9 Hz, 2H), 2.46 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 161.53, 161.47, 160.14, 143.55, 141.40, 139.32, 138.71, 137.26, 134.36, 130.14, 129.56, 129.06, 128.92, 128.85, 128.80, 128.74, 128.45, 128.35, 128.17, 127.72, 127.63, 127.49, 125.85, 124.60, 21.71; mass spectrum (ESI): m/e (% relative intensity) 588.1 (100) ($\text{M}+\text{Na}$) $^+$; HRMS calcd for $\text{C}_{31}\text{H}_{23}\text{N}_3\text{O}_3\text{S}_3\text{Na}$ ($\text{M}+\text{Na}$) $^+$ 588.0850, found 588.0857.

N-(2,6-dibenzyl-5-phenylpyrimidin-4-yl)-4-methyl-N-phenylbenzenesulfonamide(4l)

Following the general procedure B: pale yellow oil, 77%; $R_f = 0.7$ (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.51 (d, $J = 7.8$ Hz, 2H), 7.35 - 7.30 (m, 4H), 7.29 - 7.19 (m, 4H), 7.16 - 7.08 (m, 5H), 7.07 - 7.03 (m, 1H), 6.96 - 6.91 (m, 2H), 6.90 - 6.86 (m, 2H), 6.77 (d, $J = 7.08$ Hz, 2H), 6.52 (d, $J = 7.5$ Hz, 2H), 4.27 (s, 2H), 3.82 (s, 2H), 2.38 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.59, 167.76, 160.76, 143.39, 138.88, 138.36, 137.74, 136.61, 133.36, 129.86, 129.37, 129.32, 129.17, 129.03, 128.68, 128.42, 128.33, 128.30, 128.27, 128.19, 127.77, 127.53, 126.51, 126.33, 45.35, 41.28, 21.64; mass spectrum (ESI): m/e (% relative intensity) 604.2 (100) ($\text{M}+\text{Na})^+$; HRMS calcd for $\text{C}_{37}\text{H}_{31}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na})^+$ 604.2035, found 604.2047.

N-(2,6-bis(4-nitrobenzyl)-5-phenylpyrimidin-4-yl)-N-methylmethanesulfonamide (4m)

Following the general procedure B: pale yellow solid, mp: 130-132 °C, 36%; $R_f = 0.5$ (50% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 8.19 (d, $J = 8.2$ Hz, 2H), 8.03 (d, $J = 8.2$ Hz, 2H), 7.53 (d, $J = 8.1$ Hz, 2H), 7.49 - 7.44 (m, 3H), 7.20 (d, $J = 5.7$ Hz, 2H), 7.10 (d, $J = 8.1$ Hz, 2H), 4.39 (s, 2H), 4.07 (s, 2H), 2.95 (s, 3H), 2.77 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.48, 166.76, 161.11, 146.93, 146.76, 145.07, 144.89, 132.90, 130.44, 129.89, 129.73, 129.11, 128.90, 128.15, 123.68, 123.49, 44.94, 41.14, 39.77, 36.90; mass spectrum (ESI): m/e (% relative intensity) 556.1 (100) ($\text{M}+\text{Na})^+$; HRMS calcd for $\text{C}_{26}\text{H}_{23}\text{N}_5\text{O}_6\text{SNa}$ ($\text{M}+\text{Na})^+$ 556.1267, found 556.1281.

N-(2,6-bis(2-methylbenzyl)-5-phenylpyrimidin-4-yl)-N-methylmethanesulfonamide (4n)

Following the general procedure B: white solid, mp: 141-142 °C, 75%; $R_f = 0.6$ (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.40 - 7.33 (m, 3H), 7.27 - 7.23 (m, 1H), 7.21 - 7.10 (m, 5H), 7.10 - 6.99 (m, 3H), 6.78 (d, $J = 7.4$ Hz, 1H), 4.28 (s, 2H), 3.93 (s, 2H), 2.83 (s, 3H), 2.68 (s, 3H), 2.26 (s, 3H), 1.98 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.02, 168.02, 160.70, 137.31, 136.64, 136.57, 136.49, 133.51, 130.54, 130.26, 130.13, 129.68, 129.12, 128.80, 128.35, 127.56, 126.86, 126.50, 125.94, 125.81, 43.01, 39.52, 38.85, 37.02, 37.01, 19.81, 19.78; mass spectrum (ESI): m/e (% relative intensity) 494.2 (100) ($\text{M}+\text{Na})^+$; HRMS calcd for $\text{C}_{28}\text{H}_{29}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{Na})^+$ 494.1878, found 494.1888.

N-(2,6-bis(3-methoxybenzyl)-5-phenylpyrimidin-4-yl)-N-methylmethanesulfonamide (4o)

Following the general procedure B: colourless oil, 72%; $R_f = 0.5$ (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.44 - 7.37 (m, 3H), 7.24 - 7.18 (m, 3H), 7.08 (t, $J = 7.9$ Hz, 1H), 6.98 - 6.89 (m, 2H), 6.78 (d, $J = 8.2$ Hz, 1H), 6.69 (d, $J = 8.2$ Hz, 1H), 6.54 (s, 2H), 4.28 (s, 2H), 3.93 (s, 2H), 3.77 (s, 3H), 3.67 (s, 3H), 2.97 (s, 3H), 2.70 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.71, 168.00, 160.71, 159.74, 159.50, 139.41, 139.24, 133.50, 130.00, 129.43, 129.26, 128.72, 128.40, 127.61, 121.92, 121.35, 115.00, 114.39, 112.27, 112.21, 55.23, 55.22, 55.10, 45.44, 41.46, 39.63, 37.00; mass spectrum (ESI): m/e (% relative intensity) 526.2 (100) ($\text{M}+\text{Na})^+$; HRMS calcd for $\text{C}_{28}\text{H}_{29}\text{N}_3\text{O}_4\text{SNa}$ ($\text{M}+\text{Na})^+$ 526.1776, found 526.1790.

N-(2,6-bis(4-methoxybenzyl)-5-phenylpyrimidin-4-yl)-N-methylmethanesulfonamide (4p)

Following the general procedure B: white solid, mp: 125-127 °C, 81%; $R_f = 0.3$ (20% EtOAc/Petroleum Ether); ^1H NMR (600 MHz, CDCl_3) δ 7.44 - 7.38 (m, 3H), 7.29 (d, $J = 7.9$ Hz, 2H), 7.18 (d, $J = 7.0$ Hz, 2H), 6.90 - 6.84 (m, 4H), 6.71 (d, $J = 7.9$ Hz, 2H), 4.24 (s, 2H), 3.89 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 2.98 (s, 3H), 2.71 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.16, 168.41, 160.59,

158.34, 158.20, 133.56, 130.55, 130.10, 129.97, 129.81, 128.68, 128.32, 127.41, 113.84, 113.70, 55.32, 55.31, 55.25, 55.23, 44.50, 40.53, 39.62, 37.02, 37.01; mass spectrum (ESI): m/e (% relative intensity) 526.2 (100) ($M+Na$)⁺; HRMS calcd for $C_{28}H_{29}N_3O_4SNa$ ($M+Na$)⁺ 526.1776, found 526.1800.

N-(2,6-bis(4-bromobenzyl)-5-phenylpyrimidin-4-yl)-N-methylmethanesulfonamide (4q)

Following the general procedure B: white solid, mp: 166-168 °C, 94%; $R_f = 0.51$ (20% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl₃) δ 7.46-7.38 (m, 5H), 7.29 (d, $J = 7.6$ Hz, 2H), 7.22 (d, $J = 7.6$ Hz, 2H), 7.18 (d, $J = 6.5$ Hz, 2H), 6.81 (d, $J = 7.7$ Hz, 2H), 4.23 (s, 2H), 3.88 (s, 2H), 2.96 (s, 3H), 2.72 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 169.36, 167.63, 160.76, 136.79, 136.58, 133.27, 131.53, 131.37, 131.34, 130.75, 129.85, 128.87, 128.57, 127.74, 120.57, 120.52, 44.70, 40.79, 39.66, 36.97; mass spectrum (ESI): m/e (% relative intensity) 622.0 (100) ($M+Na$)⁺; HRMS calcd for $C_{26}H_{23}Br_2N_3O_2S$ (M)⁻ 597.9878, found 597.9870.

N-(2,6-bis(2-fluorobenzyl)-5-phenylpyrimidin-4-yl)-N-methylmethanesulfonamide (4r)

Following the general procedure B: pale yellow solid, mp: 95-97 °C, 91%; $R_f = 0.3$ (20% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl₃) δ 7.46 - 7.35 (m, 3H), 7.31 - 7.27 (m, 1H), 7.26 - 7.20 (m, 3H), 7.19 - 7.13 (m, 1H), 7.11 - 6.96 (m, 4H), 6.94 - 6.89 (m, 1H), 4.31 (s, 2H), 4.00 (s, 2H), 2.90 (s, 3H), 2.70 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 168.98, 167.02, 162.10 - 161.48 (d, $J = 93.0$ Hz), 160.71, 160.47 - 159.85 (d, $J = 93.0$ Hz), 133.18, 131.89 - 131.87 (d, $J = 3.0$ Hz), 131.10 - 131.08 (d, $J = 3.0$ Hz), 129.63, 128.82, 128.45 - 128.39 (d, $J = 9.0$ Hz), 128.26, 128.20 (d, $J = 9.0$ Hz), 127.71, 124.91, 124.80, 124.01 - 123.99 (d, $J = 3.0$ Hz), 123.86 - 123.84 (d, $J = 3.0$ Hz), 115.27 - 115.14 (d, $J = 19.5$ Hz), 115.13 - 115.00 (d, $J = 19.5$ Hz), 39.48, 38.18 - 38.17 (d, $J = 1.5$ Hz), 37.02, 34.42 - 34.41 (d, $J = 1.5$ Hz); ¹⁹F NMR (564 MHz, CDCl₃): δ -116.69 -- 116.72 (m, 1F), -117.07 -- 116.10 (m, 1F); mass spectrum (ESI): m/e (% relative intensity) 502.1 (100) ($M+Na$)⁺; HRMS calcd for $C_{26}H_{23}F_2N_3O_2SNa$ ($M+Na$)⁺ 502.1377, found 502.1381.

N-(2,6-bis(4-fluorobenzyl)-5-phenylpyrimidin-4-yl)-4-methyl-N-phenylbenzenesulfonamide (4s)

Following the general procedure B: colorless oil, 69%; $R_f = 0.8$ (20% EtOAc/Petroleum Ether); ¹H NMR (600 MHz, CDCl₃) δ 7.51 (d, $J = 7.2$ Hz, 2H), 7.33 - 7.27 (m, 3H), 7.24 - 7.20 (m, 2H), 7.15 (d, $J = 7.8$ Hz, 2H), 7.11 - 7.06 (m, 1H), 7.03 - 6.98 (m, 2H), 6.97 - 6.93 (m, 2H), 6.80 (d, $J = 7.2$ Hz, 4H), 6.74 (d, $J = 6.6$ Hz, 2H), 6.51 (d, $J = 6.6$ Hz, 2H), 4.27 (s, 2H), 3.81 (s, 2H), 2.41 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 168.99, 167.18, 162.59 - 162.39 (d, $J = 30.0$ Hz), 161.16, 160.97 - 160.77 (d, $J = 30.0$ Hz), 143.61, 138.67, 136.44, 133.54, 132.90, 130.84 - 130.79 (d, $J = 7.5$ Hz), 130.49 - 130.44 (d, $J = 7.5$ Hz), 129.68, 129.21, 129.18, 128.71, 128.39, 128.07, 127.95, 127.69, 115.28 - 115.14 (d, $J = 21.0$ Hz), 115.06 - 114.92 (d, $J = 21.0$ Hz), 44.07, 40.07, 21.62; ¹⁹F NMR (564 MHz, CDCl₃) δ -116.46; mass spectrum (ESI): m/e (% relative intensity) 640.2 (100) ($M+Na$)⁺; HRMS calcd for $C_{37}H_{29}F_2N_3O_2SNa$ ($M+Na$)⁺ 640.1846, found 640.1851.

General Procedure C for TfOH-Mediated [2+2+2] Cycloadditions of Ynamides with Two Difficult Nitriles.


To a suspension of ynamide **1a** (0.15 mmol), acetonitrile (31.0 μ L, 0.60 mmol), benzonitrile (61.0 μ L,

0.60 mmol), and 4Å MS (20.0 mg) in dry CH_2Cl_2 (2.00 mL) was added TfOH dropwise (21.0 μl , 0.24 mmol) via a syringe pump at -40 °C under nitrogen atmosphere. The reaction was monitored by TLC, when progress appeared to be completed after about 1.0 h at the same temperature, the saturated sodium bicarbonate solution was added to the mixture and the resulting mixture was extracted with EtOAc. The organic layers were washed with sat aq NaCl and dried over MgSO_4 . Filtration and concentration of the mixture in vacuo afforded the crude product that was purified by flash silica gel column chromatography [gradient eluent: EtOAc in petroleum ether] to obtain the corresponding products.

4-methyl-N-(6-methyl-2,5-diphenylpyrimidin-4-yl)-N-phenylbenzenesulfonamide (7a)

Following the general procedure C: white solid, mp: 188-190 °C, 39%; R_f = 0.55 (20% EtOAc/Petroleum Ether); ^1H NMR (500 MHz, CDCl_3) δ 7.68 (d, J = 8.5 Hz, 2H), 7.25 -7.17 (m, 6H), 7.16 -7.10 (m, 4H), 7.09 - 7.03 (m, 1H), 6.99 - 6.92 (m, 2H), 6.87 (d, J = 7.5 Hz, 2H), 6.62 (d, J = 7.5 Hz, 2H), 2.79 (s, 3H), 2.43 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 167.01, 166.18, 161.24, 143.55, 138.67, 137.41, 136.49, 133.61, 130.35, 129.51, 128.93, 128.85, 128.57, 128.23, 128.14, 127.76, 127.46, 127.41, 126.89, 25.48, 21.62.; mass spectrum (ESI): m/e (% relative intensity) 492.0 (100) ($\text{M}+\text{H})^+;$ HRMS calcd for $\text{C}_{30}\text{H}_{25}\text{N}_3\text{O}_2\text{SNa}$ ($\text{M}+\text{H})^+$ 492.1746, found 492.1739.


Table 1: Screening of Conditions^a





Enter	<i>C</i> (mol/L)	MeCN (<i>n</i> equiv)	PhCN (<i>n</i> equiv)	TfOH (<i>n</i> equiv)	Yield ^b (%)
1	0.075	1.1	1.1	1.6	4a : 18%, 5a : 14%, 7a , 3a : trace
2	0.075	2	2	1.6	4a : 13%, 5a : 13%, 7a : 26%, 3a : <5%
3	0.075	4	4	1.6	4a : 15%, 5a : 15%, 7a : 39%, 3a : 18%
4	0.075	6	6	1.6	4a : 18%, 5a : 18%, 7a : 28%, 3a : 24%
5	0.075	4	3	1.6	4a : 16%, 5a : 18%, 7a : 23%, 3a : 21%
6	0.075	3	4	1.6	4a : 19%, 5a : 17%, 7a : 25%, 3a : 16%


^aYnamides **1a** (0.15 mmol), TfOH (0.24 mmol), CH₂Cl₂ (2.0 mL), 20 mg 4 Å MS, -40 °C, N₂. ^bIsolated yield; the ratio(**4a**:**5a**) was determined by ¹H NMR spectroscopic analysis of the isolated mixture..


Spectra data




















S20












7.784
7.772
7.358
7.345
7.267


— 3.012
2.457
2.247
2.235
2.224
1.477
1.465
1.453
1.441
1.429
1.393
1.381
1.369
1.356
1.344
1.333
0.908
0.896
0.884








































7.433
7.423
7.414
7.412
7.266
7.017
7.004
6.990

4.493
4.479
4.017
4.004

-0.000





— 163.35
— 161.70
— 155.92


< 133.72
< 133.66


< 118.20
< 118.18
— 115.69
< 115.54


< 78.58
< 77.25
— 77.04
— 76.83
— 70.16
< 63.08
< 63.06


— 47.00





















8.008
7.995
—
7.503
—
7.310


—
5.943


—
2.573
—
2.434
—
2.236
























7.421
7.416
7.330
7.322
7.256
7.247
7.245
6.761

5.572
5.557
5.542


4.614
4.599
4.585
4.164
4.148
4.133


— 2.655


— 2.226





3g








































7.576
7.563
7.292
7.279


4.470
4.458


3.126


2.657
2.559
2.434


1.456
1.445
1.433











































7.486
7.474
7.462
7.442
7.430
7.418
7.376
7.350
7.338
7.269


4.032
3.770
3.698
3.647
3.195
2.789












































169.71
168.00
160.71
159.74
159.50


139.41
139.24
133.50
130.00
129.43
129.26
128.72
128.40
127.61
121.92
121.35
115.00
114.39
112.27
112.21


77.37
77.16
76.95


55.23
55.10
45.44
41.46
39.63
37.00






























S108

